Working with our Munich Office

In 2017 we opened our first office in mainland Europe – in Munich, Germany. This represented an important step in the expansion of our IP services and has further cemented our position as one of Europe’s leading specialist IP firms.

From Munich we offer the full range of patent, trade mark and design services, including drafting, prosecution, oppositions and appeals, dispute resolution, IP strategy consulting and portfolio management.

Our Munich base not only enhances our ability to service our EU-based clients, but also our numerous international clients. In addition to seamlessly continuing to provide trade mark and design services at the EUIPO following Brexit, we can also now provide our clients with services focussed on German national rights, representing our clients directly before the German Patent and Trade Mark Office (DPMA), and the German Federal Patent Court. Mewburn Ellis is one of a small number of firms in Europe that is capable of representing clients in this way, and this has been extremely well received by our clients.

Read our Blogs

In vivo Cell Therapy: Breaking Free of the Chains of Ex Vivo Engineering

In vivo Cell Therapy: Breaking Free of the Chains of Ex Vivo Engineering

by Adam Gregory

In vivo cell therapy is emerging as a groundbreaking approach to reduce the cost and expand the availability of cell therapies. Unlike traditional ex vivo approaches where cells are extracted, ...

Historical infringement at the UPC and selecting remedies à la carte

Historical infringement at the UPC and selecting remedies à la carte

by Matthew Naylor

2025 Week 11 The UPC has already made it clear that you can sue for damages for patent infringement dating back to before the UPC came into force (1 June 2023). This week, in Hurom v NUC Electronics, ...

Innovations in antibody-drug conjugates and bispecific antibodies – what you need to know - a new special report

Innovations in antibody-drug conjugates and bispecific antibodies – what you need to know - a new special report

by Helen Brew Gerlach

We are delighted to release our latest report Innovations in antibody-drug conjugates and bispecific antibodies – what you need to know. View the report here.

HutanBio: algae is the fuel of the future

HutanBio: algae is the fuel of the future

by Simon Kremer

Algae converts sunlight and carbon dioxide into flammable hydrocarbons, offering a like-for-like replacement for fossil fuels.

UPC Weekly - Some plain speaking from the UPC – on its existence and ambushes

UPC Weekly - Some plain speaking from the UPC – on its existence and ambushes

by Matthew Naylor

2025 Week 12 There used to be a great rule-of-thumb for reading the headlines of certain British newspapers: if the headline was posed as a controversial question, then the answer to the question is ...

Quantum Tech Down Under

Quantum Tech Down Under

by Joshua Tall

This week, Quantum Australia announced Petra Andrén has been appointed as its new CEO. Established in May 2024 with an AUD 18.4 million grant from the Department of Industry, Science and Resources, ...

In vivo Cell Therapy: Breaking Free of the Chains of Ex Vivo Engineering

In vivo Cell Therapy: Breaking Free of the Chains of Ex Vivo Engineering

by Adam Gregory

In vivo cell therapy is emerging as a groundbreaking approach to reduce the cost and expand the availability of cell therapies. Unlike traditional ex vivo approaches where cells are extracted, ...

Historical infringement at the UPC and selecting remedies à la carte

Historical infringement at the UPC and selecting remedies à la carte

by Matthew Naylor

2025 Week 11 The UPC has already made it clear that you can sue for damages for patent infringement dating back to before the UPC came into force (1 June 2023). This week, in Hurom v NUC Electronics, ...

Innovations in antibody-drug conjugates and bispecific antibodies – what you need to know - a new special report

Innovations in antibody-drug conjugates and bispecific antibodies – what you need to know - a new special report

by Helen Brew Gerlach

We are delighted to release our latest report Innovations in antibody-drug conjugates and bispecific antibodies – what you need to know. View the report here.

HutanBio: algae is the fuel of the future

HutanBio: algae is the fuel of the future

by Simon Kremer

Algae converts sunlight and carbon dioxide into flammable hydrocarbons, offering a like-for-like replacement for fossil fuels.

UPC Weekly - Some plain speaking from the UPC – on its existence and ambushes

UPC Weekly - Some plain speaking from the UPC – on its existence and ambushes

by Matthew Naylor

2025 Week 12 There used to be a great rule-of-thumb for reading the headlines of certain British newspapers: if the headline was posed as a controversial question, then the answer to the question is ...

Quantum Tech Down Under

Quantum Tech Down Under

by Joshua Tall

This week, Quantum Australia announced Petra Andrén has been appointed as its new CEO. Established in May 2024 with an AUD 18.4 million grant from the Department of Industry, Science and Resources, ...

Read our news and insights

Our Growing Team

Our Munich office is a fully operational Mewburn Ellis office. We have invested in it heavily, and we have worked hard to grow it from the ground up. We are proud to say that our Munich team has increased to a significant size, and we now have over 15 colleagues permanently based in our Munich office. We intend to expand further too.

Led by partner Tanis Keirstead, the Munich team currently includes five partners. In addition to Tanis there are three German patent attorney partners and one German trade mark partner. We also have three qualified attorneys together with a number of highly skilled German paralegals “Patentanwaltsfachangestellte”) who work alongside them to offer a high quality and stable service for clients looking for EUIPO, DPMA and EPO services.

As such, our Munich team include patent specialists who work across the engineering, life sciences and chemistry technical fields; as well as experienced trade mark attorneys with expertise across all aspects of German, European and international trade mark law.

The Munich team work closely and effectively with UK based colleagues to ensure our clients benefit from the entire depth and breadth of expertise available within Mewburn Ellis.

Open pages of Guide to the Unitary Patent and Unified Patent Court

Guide to the Unitary Patent and the Unified Patent Court

This is a significant change that has different implications depending on business goals as well as your sector and size of business.

Find out more detail about the Unitary Patent and Unified Patent Court with our detailed guide. This covers a summary overview of both as well as details around costs and processes to obtain a unitary patent and a comparison of pros and cons.

Download here

A Harmonised Approach

In recent years, the cost of filing and prosecuting applications at the EPO has risen. Together with the relatively strict examination at the EPO, many international applicants are now looking to the national route instead of the EPO - in particular, they are looking at filing UK and German patent applications instead of EP applications. At Mewburn Ellis we are extremely well placed to service this renewed interest in the national route.

We offer a one-stop shop for filing and prosecuting UK and German national patent applications. Further, our integrated way of working means that our clients benefit greatly from our UK and German attorneys working closely with one another on related cases across the portfolio. On the one hand, our integrated approach leads to appreciable cost benefits for our clients, resulting from streamlined advice and simpler lines of communication. On the other hand, it leads to a more harmonised approach in the management of their UK and German patent portfolios, which ultimately strengthens our clients’ IP position in the marketplace.

Forward Magazines Overlapping 8

Mewburn Ellis

FORWARD MAGAZINE

Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.